Tag: ROR gamma (t)
Company News: Lead Pharma to Partner with Sanofi on Development of Treatments for Autoimmune Diseases
– R&D collaboration and license agreement may yield potential first-in-class oral anti-ROR gamma (t) therapies
Lead Pharma, a pharmaceutical company developing innovative medicines for the treatment of autoimmune diseases and cancer, today announced that it has entered into a research collaboration and license agreement with Sanofi to discover, develop and commercialize small molecule therapies directed against the nuclear hormone receptor ROR gamma (t) to treat a broad range of autoimmune disorders, including common diseases such as rheumatoid arthritis and inflammatory bowel disease.
Researchers have identified 80 to 100 different autoimmune disorders and suspect at least an additional 40 diseases of being driven by immune function. These diseases are chronic and can be life-threatening.
Under the terms of the agreement, Lead Pharma will receive an upfront payment and is eligible to receive research, development, regulatory and commercial milestone payments. Further details of the financial terms have not been disclosed. Sanofi is responsible for clinical development and will have worldwide marketing and commercialization rights to any products that may be developed as a result of the collaboration. Lead Pharma is entitled to receive royalty payments on global sales from any such products.